A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

NCT04631016 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

137

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)
Chronic Bronchitis

Interventions

DRUG: Tozorakimab
OTHER: Placebo

Sponsor

AstraZeneca